When was MediPrint founded?

MediPrint was founded in 2001 and raised its 1st funding round 19 years after it was founded.

Where is MediPrint located?

MediPrint is headquartered in San Diego, United States.

How many employees does MediPrint have?

As of Jul 01, 2024, the latest employee count at MediPrint is 6.

Is MediPrint a funded company?

MediPrint is a funded company, having raised a total of $11.4M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 09, 2020.

When was the latest funding round of MediPrint?

MediPrint's latest funding was a $***** Series A round on Mar 15, 2022, with participation from 0 investor.

Where does MediPrint rank among its competitors?

MediPrint ranks 4th amongst 35 active competitors, of which 12 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Eyenovia, which secured $50M in Jun, 2025.

Who are the top competitors of MediPrint?

MediPrint's top competitors include Eyenovia, PolyActiva and Re-Vana Therapeutics. Among them, Eyenovia secured the most recent funding round in June, 2025.

MediPrint - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of technology for ocular drug delivery. The company has developed proprietary printing technology and ink that allows sustained, continuous release of ophthalmic drugs via contact lenses to treat glaucoma, dry eye, myopia, and others.

Website: mediprintlens.com
Email ID: *****@leolens.com
Phone Number: +1 **********

Key Metrics

Founded Year

2001

Location

San Diego, United States

Stage

Series A

Total Funding

$11.4M in 3 rounds

Latest Funding Round

Series A, Mar 15, 2022, $*****

Ranked

4^th among 35 active competitors

Employee Count

6 as on Jul 01, 2024

Similar Companies

Eyenovia & 37 more

View MediPrint's full profile

MediPrint has raised a total funding of $11.4M over 3 rounds. Its first funding round was on Dec 09, 2020.

Here is the list of recent funding rounds of MediPrint:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 15, 2022	9704600	Series A	9776811	2208528	9702594	9625500
Jan 26, 2021	6744423	Series A	5129347	1033900	9444593	8548863
Dec 09, 2020	9876428	Series A	6384565	9172395	3428172	5781421

Access funding benchmarks and valuations. Sign up today!

View details of MediPrint's funding rounds and investors

The founders of MediPrint is Praful Doshi.

Here are the details of MediPrint's key team members:

Praful Doshi: Founder of MediPrint and founder of 1 other company.
Contact Info: 2 email addresses
Dan Myers: CEO of MediPrint.

View details of MediPrint's Founder profiles and Board Members

MediPrint's employee count trend

MediPrint has 6 employees as of Jul 24. Here is MediPrint's employee count trend over the years:

Uncover MediPrint's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MediPrint include Eyenovia, PolyActiva and Re-Vana Therapeutics. Here is the list of Top 10 competitors of MediPrint, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Eyenovia 2014, New York City (United States), Public	Developer of microdose therapies for treating myopia	$10M	Senju Pharmaceutical, Eshelman Ventures & 3 others	57/100
2nd	PolyActiva 2010, Melbourne (Australia), Series C	Drug delivery platform	$46.7M	Brandon Capital, National Reconstruction Fund ... & 2 others	56/100
3rd	Re-Vana Therapeutics 2015, Belfast (United Kingdom), Series A	Developer of drug delivery platform forophthalmic diseases	$16.7M	Visionary Ventures, Exsight Ventures & 11 others	50/100
4th	MediPrint 2001, San Diego (United States), Series A	Developer of technology for ocular drug delivery	$11.4M	-	36/100
5th	Everads Therapy 2017, Tel Aviv (Israel), Funding Raised	Drug & a cell targeting system for posterior segment eye diseases	-	EIC Fund, RAD BioMed & 1 others	45/100
6th	Kedalion Thera 2015, Menlo Park (United States), Acquired	Provider of drug delivery system for eye diseases	$5M	Novartis, Lagunita Biosciences	44/100
7th	LayerBio 2013, Boston (United States), Acquired	Developing innovative ophthalmic therapies, including sustained-release drug delivery for cataract surgery	$205K	C2I Accelerator, National Science Foundation ... & 1 others	42/100
8th	MgShell 2019, Milano (Italy), Series A	Developer of an intraocular device for drug delivery	$1.83M	Club degli Investitori, Italian Angels for Biotech ... & 6 others	40/100
9th	Opharmic 2016, Hong Kong (China), Funding Raised	Developer of non-invasive ocular drug delivery system	-	MedTech Innovator, Pentepebble	33/100
10th	OcuMedic 2017, Mullica Hill (United States), Unfunded	Developer of drug delivery product for eyes	-	-	33/100